ストックスクリーナーアプリを入手
2.71
1.88%
0.05
アフターアワーズ：
2.65
-0.06
-2.21%
Quantum Biopharma Ltd (QNTM) 最新ニュース
Gross profit of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAN:0K91 - TradingView
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - GlobeNewswire Inc.
A passive investor reports 4.95% ownership of Quantum Biopharma (QNTM). - stocktitan.net
Free float of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAN:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Cash Flow – HAN:0K91 - TradingView
After tax other income/expense of Quantum Biopharma Ltd. Subordinate Voting Shares Class B – HAN:0K91 - TradingView
Quantum Biopharma Ltd. Subordinate Voting Shares Class B Actuals & Estimates (HAN:0K91) - TradingView
Cash runway to 2028 comes with fresh dilution at Quantum BioPharma (QNTM) - Stock Titan
Nearly 2.9 million people have MS. A drug candidate targeting nerve coating gets FDA trial clearance. - Stock Titan
Quantum BioPharma (QNTM.CN) Receives FDA Clearance for Historic Phase 2 Trial of Lucid-MS in Multiple Sclerosis - kalkine.ca
Quantum BioPharma Ltd.: Financial Data Forecasts Estimates and Expectations | QNTM | CA74764Y2050 - marketscreener.com
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance - The Chronicle-Journal
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Australia
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Canada
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com India
Quantum BioPharma receives FDA clearance for MS phase 2 trial - Investing.com
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com UK
Quantum BioPharma Ltd. Receives FDA Clearance To Begin Phase 2 Trial Of Lucid-MS For Multiple Sclerosis - marketscreener.com
Quantum BioPharma receives FDA clearance for MS phase 2 trial By Investing.com - Investing.com Nigeria
Quantum Biopharma amends Form 6-K to add exhibit to F-3 registration statement - Bitget
Quantum Biopharma (QNTM) folds April 2 press release into shelf filing - Stock Titan
April press release now tied to Quantum Biopharma (QNTM) securities registration - Stock Titan
March 30 release now part of Quantum Biopharma (QNTM) registration - Stock Titan
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach - Almaguin News
Why Did Quantum BioPharma (CN:TCM) Stock Surge 6.846% on 4 September 2026? - kalkine.ca
FDA Clears Quantum BioPharma’s Lucid-MS Phase 2 Trial — Could QNTM Be Entering a Pivotal Clinical Chapter? - kalkine.ca
Quantum BioPharma Stock Slides 5.75%: Is Clinical Execution Risk Weighing on QNTM Sentiment? - kalkine.ca
Quantum BioPharma Stock Slides 5.75% as CN:QNTM Delisting Plans Add Fresh Pressure to QNTM Sentiment - kalkine.ca
2026-0904DelistQuantum BioPharma Ltd. (QNTM) - The Canadian Securities Exchange (CSE)
Giving up one stock exchange but not Nasdaq, Quantum BioPharma (NASDAQ: QNTM) reshapes where its shares trade - Stock Titan
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - marketscreener.com
Quantum BioPharma to Delist Class B Shares from Canadian Securities Exchange - Yahoo Finance
Quantum BioPharma Ltd. Applies for Voluntary Delisting of Class B Shares from Canadian Securities Exchange - Quiver Quantitative
Quantum BioPharma to Voluntarily Delist Class B Shares from CSE, Consolidating Trading on Nasdaq - kalkine.ca
Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange - Yahoo Finance
QNTM Initiated Coverage by Rodman & Renshaw -- Price Target Set at $8.00 - GuruFocus
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - TradingView
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - Benzinga
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential - The Globe and Mail
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com Nigeria
Quantum BioPharma Ltd. (CN:QNTM) Rises 3.07% as FDA-Cleared Lucid-MS Program Strengthens Investor Optimism - kalkine.ca
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com
QNTM Stock Analysis: Price-to-Sales Signals Market Skepticism De - GuruFocus
Quantum BioPharma stock initiated with buy rating at Rodman & Renshaw - Investing.com India
Quantum BioPharma Shares Slip 4.44% as Clinical Risk and Biotech Volatility Temper Sentiment - kalkine.ca
Quantum BioPharma Stock Faces Renewed Pressure as Clinical Execution Risk Tests Investor Confidence - kalkine.ca
Headline: Quantum BioPharma Stock Under Pressure After August 25 Decline — Can Lucid-MS Catalyze a Recovery? - kalkine.ca
Quantum BioPharma Falls 4.26% After FDA Clearance Rally: Profit-Taking or a Deeper Signal? - kalkine.ca
Quantum BioPharma Stock Under Pressure as Volatility and Clinical Execution Risks Weigh on Investor Sentiment - kalkine.ca
Quantum (QNTM) Technicals: Trades in a Narrow Directional Range at $3.44 at the Close; the $3.27 to $3.61 Range Remains in Focus in the Latest SessionAdvance Decline Volume - vinanet.vn
1.35%
大文字化:
|
ボリューム (24 時間):